Refino CJ - Search Results

1

Limiting systemic plasminogenolysis reduces the bleeding potential for tissue-type plasminogen activators but not for streptokinase.

Thomas GR, Thibodeaux H, Errett CJ, Badillo JM, Wu DT, Refino CJ, Keyt BA, Bennett WF. Thomas GR, et al. Among authors: refino cj. Thromb Haemost. 1996 Jun;75(6):915-20. Thromb Haemost. 1996. PMID: 8822586

2

A long-half-life and fibrin-specific form of tissue plasminogen activator in rabbit models of embolic stroke and peripheral bleeding.

Thomas GR, Thibodeaux H, Errett CJ, Badillo JM, Keyt BA, Refino CJ, Zivin JA, Bennett WF. Thomas GR, et al. Among authors: refino cj. Stroke. 1994 Oct;25(10):2072-8; discussion 2078-9. doi: 10.1161/01.str.25.10.2072. Stroke. 1994. PMID: 8091454

3

A faster-acting and more potent form of tissue plasminogen activator.

Keyt BA, Paoni NF, Refino CJ, Berleau L, Nguyen H, Chow A, Lai J, Peña L, Pater C, Ogez J, et al. Keyt BA, et al. Among authors: refino cj. Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3670-4. doi: 10.1073/pnas.91.9.3670. Proc Natl Acad Sci U S A. 1994. PMID: 8170967 Free PMC article.

4

A slow clearing, fibrin-specific, PAI-1 resistant variant of t-PA (T103N, KHRR 296-299 AAAA).

Paoni NF, Keyt BA, Refino CJ, Chow AM, Nguyen HV, Berleau LT, Badillo J, Peña LC, Brady K, Wurm FM, et al. Paoni NF, et al. Among authors: refino cj. Thromb Haemost. 1993 Aug 2;70(2):307-12. Thromb Haemost. 1993. PMID: 8236140

5

A variant of t-PA (T103N, KHRR 296-299 AAAA) that, by bolus, has increased potency and decreased systemic activation of plasminogen.

Refino CJ, Paoni NF, Keyt BA, Pater CS, Badillo JM, Wurm FM, Ogez J, Bennett WF. Refino CJ, et al. Thromb Haemost. 1993 Aug 2;70(2):313-9. Thromb Haemost. 1993. PMID: 8236141

6

Optimized thrombolysis of cerebral clots with tissue-type plasminogen activator in a rabbit model of embolic stroke.

Thomas GR, Thibodeaux H, Bennett WF, Refino CJ, Badillo JM, Errett CJ, Zivin JA. Thomas GR, et al. Among authors: refino cj. J Pharmacol Exp Ther. 1993 Jan;264(1):67-73. J Pharmacol Exp Ther. 1993. PMID: 8423552

7

An experimental model of intracranial hemorrhage during thrombolytic therapy with t-PA.

Paoni NF, Steinmetz HG, Gillett N, Refino CJ, Badillo JM, Bunting S. Paoni NF, et al. Among authors: refino cj. Thromb Haemost. 1996 May;75(5):820-6. Thromb Haemost. 1996. PMID: 8725730

8

Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog.

Collen D, Stassen JM, Yasuda T, Refino C, Paoni N, Keyt B, Roskams T, Guerrero JL, Lijnen HR, Gold HK, et al. Collen D, et al. Thromb Haemost. 1994 Jul;72(1):98-104. Thromb Haemost. 1994. PMID: 7974384

9

New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA.

Benedict CR, Refino CJ, Keyt BA, Pakala R, Paoni NF, Thomas GR, Bennett WF. Benedict CR, et al. Among authors: refino cj. Circulation. 1995 Nov 15;92(10):3032-40. doi: 10.1161/01.cir.92.10.3032. Circulation. 1995. PMID: 7586274

10

The influence of carbohydrate structure on the clearance of recombinant tissue-type plasminogen activator.

Hotchkiss A, Refino CJ, Leonard CK, O'Connor JV, Crowley C, McCabe J, Tate K, Nakamura G, Powers D, Levinson A, et al. Hotchkiss A, et al. Among authors: refino cj. Thromb Haemost. 1988 Oct 31;60(2):255-61. Thromb Haemost. 1988. PMID: 2851193

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

29 results

Search Page

Filters